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Background: Contrast dye has, on average, 150-350 mg/mL of iodine, whereas the daily recommended iodine intake is only 150mcg. At these 
doses the thyroid’s compensatory mechanisms may fail, leading to thyroiditis and thyrotoxicosis (TTx). However, the incidence of TTx after cardiac 
catheterization is unknown.
Methods: Patients (N=957) who received >100 mL of contrast at cardiac angiography, had no prior history of thyroid disease and had a recent 
thyroid stimulating hormone (TSH) test were evaluated. Cases were matched 1:5 by age (±5 years) and sex to controls (N=4,785). Controls had no 
history of thyroid disease or angiography. Follow-up for both groups included a TSH level at 2 weeks-6 months, (cases: after angiography, controls: 
after baseline TSH) and any subsequent TSH during the follow-up period (maximum: 5 yrs). Incident TTx was defined by ICD-9 code. Changes in TSH 
were compared using the non-parametric Kruskal-Wallis test.
Results: Cases received an average of 183.0±96.6 mL of contrast. Compared to controls, cases had a higher incidence of diabetes, hypertension, 
and hyperlipidemia (43.4% vs. 24.5%, 77.5% vs. 54.7%, and 71.6% vs. 54.7%, respectively, p<0.001 for all). At 6 months there was no significant 
change in TSH for cases or controls when compared to baseline (cases: 3.6±12.2, median: 1.9 vs. 3.0±1.9, median: 1.9; controls: 2.7±6.5, median: 
1.7 vs. 2.3±3.7, median: 1.7). However, there was a significant increase in the incidence of TTx in the cases at 6-months (1.4% vs. 0.05%, p=0.002), 
1-year (1.9% vs.1.1%, p=0.03) and over the long-term (3.8% vs. 1.6%, p<0.0001). After adjustment, the increased risk of TTx for cases remained 
significant: 6 months: OR=2.80, p=0.005; 1 year: OR=1.79, p=0.04. No interaction between sex and incidence of TTx was found at any of the time 
points.
Conclusions: In patients without a history of thyroid disease, contrast use >100 mL at angiography is a significant risk factor for the subsequent 
development of TTx. This novel observation should prompt additional studies to identify patients that are at greatest risk of developing TTx after 
angiography.
